Related Experiment Video

Updated: Aug 19, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study

E Onesti1, F Bagnato, V Tomassini

  • 1Department of Neurological Sciences, La Sapienza University of Rome, Viale dell'Università 30, I-00185 Rome, Italy.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|January 13, 2004
PubMed

Insights

Interferon beta-1b (IFNbeta-1b) significantly reduced relapse frequency in multiple sclerosis (MS) patients in a real-world setting. Post-marketing studies are crucial for assessing drug effectiveness and safety in daily clinical practice.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Interferon beta-1b (IFNbeta-1b) is an established immunomodulatory treatment for MS.
  • Post-marketing studies are essential for evaluating drug performance in routine clinical practice.

Purpose of the Study:

  • To assess the real-world impact of interferon beta-1b (IFNbeta-1b) on patients with relapsing-remitting multiple sclerosis (RRMS).
  • To compare relapse frequency and Expanded Disability Status Scale (EDSS) scores in treated versus untreated RRMS patients over three years.

Main Methods:

  • A post-marketing study involving 166 RRMS patients (83 treated with IFNbeta-1b, 83 untreated).
  • Comparison of annualized relapse frequency and mean EDSS scores over a three-year period.
  • Analysis of safety and tolerability in a daily clinical setting.

Main Results:

  • Patients treated with IFNbeta-1b showed a significant decrease in annualized relapse frequency.
  • No statistically significant changes were observed in the mean EDSS score for the treated group.
  • The study highlighted the safety and tolerability of IFNbeta-1b in clinical practice.

Conclusions:

  • Post-marketing surveillance effectively evaluates the impact of approved therapies like IFNbeta-1b in routine care.
  • IFNbeta-1b demonstrates a positive effect in reducing inflammatory events (relapses) in RRMS patients.
  • Real-world data confirms the clinical utility of immunomodulatory treatment for MS.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...